



EBMT Centre Identification Code (CIC): _____
Hospital Unique Patient Number (UPN): _____
Patient Number in EBMT Registry: _____

Treatment Type HCT CT IST Other
Treatment Date ____/____/____ (YYYY/MM/DD)

NON-INDICATION DIAGNOSIS

Date of diagnosis: ____/____/____ (YYYY/MM/DD)

Classification:

<input type="checkbox"/> Acute leukaemias
<input type="checkbox"/> Autoimmune disorders
<input type="checkbox"/> Bone marrow failure syndromes including aplastic anaemia (BMF incl. AA)
<input type="checkbox"/> Chronic leukaemias
<input type="checkbox"/> Haemoglobinopathies
<input type="checkbox"/> Lymphomas
<input type="checkbox"/> MDS/MPN overlap syndromes
<input type="checkbox"/> Myelodysplastic neoplasms (MDS)
<input type="checkbox"/> Myeloproliferative neoplasms (MPN)
<input type="checkbox"/> Plasma cell neoplasms (PCN)
<input type="checkbox"/> Solid tumours

Acute leukaemias

Classification:

<input type="checkbox"/> Acute myeloid leukaemia (AML)
<input type="checkbox"/> Precursor lymphoid neoplasm (ALL)
<input type="checkbox"/> Other acute leukaemia

Acute Myeloid Leukaemias

AML with myelodysplasia related changes?

- No
- Yes; **Was there a previous diagnosis of MDS, MPN or MDS/MPN?** No Yes (complete the respective diagnosis form in addition to the current form)
- Unknown

Therapy related myeloid neoplasia (old "secondary acute leukaemia")? No

- Related to prior treatment but **not** after a previous diagnosis of MDS, MPN or MDS/MPN*
- Yes (complete the respective diagnosis form in addition to the current form)
- Unknown

(If therapy related myeloid neoplasia, is Yes)

- Is this a donor cell leukaemia?** No Yes
- Not applicable (no previous allo HCT)
- Unknown

Autoimmune disorders

Classification:

Connective tissue:

- Systemic sclerosis (SSc, scleroderma)

SSc type:

- diffuse cutaneous
 limited cutaneous
 SSc sine scleroderma
 Other SSc type; specify: _____

- Systemic lupus erythematosus (SLE)
 Mixed connective tissue disease (MCTD)
 Polymyositis/Dermatomyositis (PM/DM)
 Sjögren syndrome
 Antiphospholipid syndrome
 Other connective tissue disease; specify: _____

Vasculitis:

- Granulomatosis with polyangiitis (GPA); *formerly Wegener granulomatosis*
 Classical polyarteritis nodosa
 Microscopic polyarteritis nodosa
 Eosinophilic granulomatosis with polyangiitis (EGPA); *formerly Churg-Strauss*
 Behçet syndrome
 Takayasu arteritis
 Other vasculitis; specify: _____

Arthritis:

- Adult onset stills disease (AOSD)
 Rheumatoid arthritis
 Psoriatic arthritis/psoriasis
 Juvenile idiopathic arthritis (JIA), systemic (Still's disease)
 Juvenile idiopathic arthritis (JIA), articular
 oligoarticular onset
 polyarticular onset
 Other juvenile idiopathic arthritis; specify: _____
 Other arthritis; specify: _____

Autoimmune disorders

Classification (continued):

Neurological diseases:

- Multiple sclerosis
- Myasthenia gravis
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Neuromyelitis optica (NMO) or NMO spectrum disorders (NMOSD)
- Other autoimmune neurological disorder; specify: _____

Haematological diseases:

- Idiopathic thrombocytopenic purpura (ITP)
- Haemolytic anaemia
- Evans syndrome
- Autoimmune lymphoproliferative syndrome (primary diagnosis, not subsequent to transplant)
- Other haematological autoimmune disease; specify: _____

Inflammatory bowel diseases:

- Celiac disease
- Crohn's disease
- Ulcerative colitis
- Other autoimmune bowel disease; specify: _____

Other autoimmune/autoinflammatory diseases:

- Insulin-dependent diabetes mellitus (IDDM)
- VEXAS syndrome
- Other autoimmune disease; specify: _____

Only for VEXAS syndrome:

- Which form of VEXAS syndrome:** Without concurrent MDS
 With concurrent MDS (**Complete MDS diagnosis form in addition to the current form**)
 Unknown

- How was the VEXAS diagnosis made:** Clinical diagnosis only
 Confirmed UBA1 mutation (e.g. Met41)
 Bone marrow features (e.g. vacuoles, dysplasia)
 Other method of VEXAS diagnosis, specify _____
 Unknown

Bone marrow failure syndromes (BMF) incl. aplastic anaemia (AA)

Classification:

Acquired:

<input type="checkbox"/> Aplastic anaemia (AA) <ul style="list-style-type: none"> <input type="checkbox"/> Moderate <input type="checkbox"/> Severe <input type="checkbox"/> Very Severe 	Etiology: <input type="checkbox"/> Secondary to hepatitis <input type="checkbox"/> Secondary to toxin/other drug <input type="checkbox"/> Idiopathic <input type="checkbox"/> Other; specify: _____
<input type="checkbox"/> Pure red cell aplasia (non-congenital PRCA)	
<input type="checkbox"/> PNH presentation <ul style="list-style-type: none"> <input type="checkbox"/> Haemolytic <input type="checkbox"/> Aplastic <input type="checkbox"/> Thrombotic <input type="checkbox"/> Other; specify: _____ 	
<input type="checkbox"/> Pure white cell aplasia	
<input type="checkbox"/> Amegakaryocytosis / Thrombocytopenia (non-congenital)	
<input type="checkbox"/> Other acquired cytopenic syndrome; specify: _____	

Genetic:

<input type="checkbox"/> Amegakaryocytosis / Thrombocytopenia (congenital)		
<input type="checkbox"/> Fanconi anaemia <table style="width: 100%; margin-top: 10px;"> <tr> <td style="width: 50%; vertical-align: top;"> Mutated gene: <input type="checkbox"/> FANCA <input type="checkbox"/> FANCB <input type="checkbox"/> FANCC <input type="checkbox"/> FANCD1 (BRCA2) <input type="checkbox"/> FANCD2 <input type="checkbox"/> FANCE <input type="checkbox"/> FANCF <input type="checkbox"/> FANCG <input type="checkbox"/> FANCI <input type="checkbox"/> FANCI (BRIP1) <input type="checkbox"/> FANCL </td> <td style="width: 50%; vertical-align: top;"> <input type="checkbox"/> FANCM <input type="checkbox"/> FANCN (PALB2) <input type="checkbox"/> FANCO (RAD51C) <input type="checkbox"/> FANCP (SLX4) <input type="checkbox"/> FANCQ (XPF) <input type="checkbox"/> FANCS (BRCA1) <input type="checkbox"/> FANCT (UBE2T) <input type="checkbox"/> FANCU (XRCC2) <input type="checkbox"/> FANCV (REV7) <input type="checkbox"/> FANCW (RFWD3) <input type="checkbox"/> Other; specify: _____ </td> </tr> </table>	Mutated gene: <input type="checkbox"/> FANCA <input type="checkbox"/> FANCB <input type="checkbox"/> FANCC <input type="checkbox"/> FANCD1 (BRCA2) <input type="checkbox"/> FANCD2 <input type="checkbox"/> FANCE <input type="checkbox"/> FANCF <input type="checkbox"/> FANCG <input type="checkbox"/> FANCI <input type="checkbox"/> FANCI (BRIP1) <input type="checkbox"/> FANCL	<input type="checkbox"/> FANCM <input type="checkbox"/> FANCN (PALB2) <input type="checkbox"/> FANCO (RAD51C) <input type="checkbox"/> FANCP (SLX4) <input type="checkbox"/> FANCQ (XPF) <input type="checkbox"/> FANCS (BRCA1) <input type="checkbox"/> FANCT (UBE2T) <input type="checkbox"/> FANCU (XRCC2) <input type="checkbox"/> FANCV (REV7) <input type="checkbox"/> FANCW (RFWD3) <input type="checkbox"/> Other; specify: _____
Mutated gene: <input type="checkbox"/> FANCA <input type="checkbox"/> FANCB <input type="checkbox"/> FANCC <input type="checkbox"/> FANCD1 (BRCA2) <input type="checkbox"/> FANCD2 <input type="checkbox"/> FANCE <input type="checkbox"/> FANCF <input type="checkbox"/> FANCG <input type="checkbox"/> FANCI <input type="checkbox"/> FANCI (BRIP1) <input type="checkbox"/> FANCL	<input type="checkbox"/> FANCM <input type="checkbox"/> FANCN (PALB2) <input type="checkbox"/> FANCO (RAD51C) <input type="checkbox"/> FANCP (SLX4) <input type="checkbox"/> FANCQ (XPF) <input type="checkbox"/> FANCS (BRCA1) <input type="checkbox"/> FANCT (UBE2T) <input type="checkbox"/> FANCU (XRCC2) <input type="checkbox"/> FANCV (REV7) <input type="checkbox"/> FANCW (RFWD3) <input type="checkbox"/> Other; specify: _____	
<input type="checkbox"/> Diamond-Blackfan anaemia (congenital PRCA)		
<input type="checkbox"/> Shwachman-Diamond syndrome		
<input type="checkbox"/> Dyserythropoietic anaemia		
<input type="checkbox"/> Dyskeratosis congenita		
<input type="checkbox"/> Congenital sideroblastic anaemia (CSA)		
<input type="checkbox"/> Other congenital anaemia; specify: _____		

Chronic leukaemias

Classification (WHO 2022):

- | |
|--|
| <input type="checkbox"/> Chronic myeloid leukaemia (CML) |
| <input type="checkbox"/> Chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL) / Richter transformation |
| <input type="checkbox"/> Prolymphocytic (PLL) and other chronic leukaemias |

MDS/MPN overlap syndromes

Classification (WHO 2022):

- | |
|---|
| <input type="checkbox"/> Chronic myelomonocytic leukaemia (CMML, CMML) |
| <input type="checkbox"/> MDS/MPN with SF3B1 mutation and thrombocytosis |
| <input type="checkbox"/> MDS/MPN with neutrophilia (Atypical CML BCR-ABL1-negative) |
| <input type="checkbox"/> MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) |
| <input type="checkbox"/> MDS/MPN not otherwise specified (NOS) |

MDS

Therapy related MDS (Secondary origin)? No

Yes, disease related to prior exposure to therapeutic drugs or radiation

Unknown

(If therapy related MDS, is Yes)

Is this a donor cell leukaemia? No

Yes

Not applicable (no previous allo HCT)

Unknown



EBMT Centre Identification Code (CIC): ____
 Hospital Unique Patient Number (UPN): _____
 Patient Number in EBMT Registry: _____

Treatment Type HSCT CT OTHER
 Treatment Date ____/____/____ (YYYY/MM/DD)

Myeloproliferative neoplasms (MPN)

Classification at treatment (WHO 2022):

<input type="checkbox"/> Primary myelofibrosis
<input type="checkbox"/> Polycythaemia vera (PV)
<input type="checkbox"/> Essential or primary thrombocythaemia (ET)
<input type="checkbox"/> Juvenile myelomonocytic leukaemia (JCMMoL, JMML, JCML, JCMML)
<input type="checkbox"/> Hyper eosinophilic syndrome (HES)
<input type="checkbox"/> Chronic eosinophilic leukaemia (CEL)
<input type="checkbox"/> Chronic neutrophilic leukaemia (CNL)
<input type="checkbox"/> Aggressive systemic mastocytosis
<input type="checkbox"/> Systemic mastocytosis with an associated haematologic neoplasm (SM-AHN)
<input type="checkbox"/> Mast cell leukaemia
<input type="checkbox"/> Mast cell sarcoma
<input type="checkbox"/> MLN-TK with FGFR1 rearrangement
<input type="checkbox"/> MLN-TK with PDGFRA rearrangement
<input type="checkbox"/> MLN-TK with PDGFRB rearrangement
<input type="checkbox"/> MLN-TK with JAK2 rearrangement
<input type="checkbox"/> MLN-TK with FLT3 rearrangement
<input type="checkbox"/> MLN-TK with ETV6::ABL1 fusion
<input type="checkbox"/> MPN not otherwise specified (NOS)
<input type="checkbox"/> Other; specify: _____

Plasma cell neoplasms (PCN)

Classification (WHO 2022):

<input type="checkbox"/> Plasma cell (multiple) myeloma (PCM)	<input type="checkbox"/> Heavy chain and light chain	Heavy chain type:	Light chain type:
	<input type="checkbox"/> Light chain only	<input type="checkbox"/> IgG	<input type="checkbox"/> Kappa
		<input type="checkbox"/> IgA	<input type="checkbox"/> Lambda
		<input type="checkbox"/> IgD	<input type="checkbox"/> Unknown
	<input type="checkbox"/> IgE		
	<input type="checkbox"/> IgM (not Waldenstrom)		
	<input type="checkbox"/> Unknown		
<input type="checkbox"/> Non-secretory			
<input type="checkbox"/> Unknown			
<input type="checkbox"/> Plasma cell leukaemia			
<input type="checkbox"/> Solitary plasmacytoma of bone			
<input type="checkbox"/> Immunoglobulin-related (AL) amyloidosis			
<input type="checkbox"/> POEMS (Polyneuropathy, Organomegaly, Endocrinopathy/Edema, Monoclonal-protein, Skin changes)			
<input type="checkbox"/> Monoclonal immunoglobulin deposition disease			
<input type="checkbox"/> Other; specify: _____			

Lymphomas

Classification:

<input type="checkbox"/> B-cell non-Hodgkin lymphoma (NHL)
<input type="checkbox"/> T-cell non-Hodgkin lymphoma (NHL)
<input type="checkbox"/> Hodgkin lymphoma
<input type="checkbox"/> Immunodeficiency-associated lymphoproliferative disorder (incl. PTLD)
<input type="checkbox"/> Other; specify _____

Lymphomas B-Cell Non-Hodgkin Lymphomas (NHL)

Sub-Classification: Mature B-cell neoplasms

<input type="checkbox"/> Splenic B-cell lymphomas and leukaemias <ul style="list-style-type: none"> <input type="checkbox"/> Splenic marginal zone lymphoma <input type="checkbox"/> Splenic diffuse red pulp small B-cell lymphoma
<input type="checkbox"/> Lymphoplasmacytic lymphoma <ul style="list-style-type: none"> <input type="checkbox"/> IgM-LPL/ Waldenström Macroglobulinaemia (WM) type <input type="checkbox"/> Non-WM type LPL
<input type="checkbox"/> Marginal zone lymphoma <ul style="list-style-type: none"> <input type="checkbox"/> Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue <input type="checkbox"/> Primary cutaneous marginal zone lymphoma <input type="checkbox"/> Nodal marginal zone lymphoma <input type="checkbox"/> Paediatric marginal zone lymphoma
<input type="checkbox"/> Follicular lymphoma <ul style="list-style-type: none"> <input type="checkbox"/> Classical follicular lymphoma (cFL) <input type="checkbox"/> Follicular large B-cell lymphoma (FLBL) <input type="checkbox"/> FL with uncommon features (uFL)
<input type="checkbox"/> Paediatric-type follicular lymphoma
<input type="checkbox"/> Duodenal-type follicular lymphoma
<input type="checkbox"/> Cutaneous follicle centre lymphoma
<input type="checkbox"/> Mantle cell lymphoma <ul style="list-style-type: none"> <input type="checkbox"/> Mantle cell lymphoma <input type="checkbox"/> Leukaemic non-nodal mantle cell lymphoma
<input type="checkbox"/> Transformations of indolent B-cell lymphomas

Lymphomas

B-Cell Lymphoid Proliferation and Lymphomas

Sub-Classification: Mature B-cell neoplasms

- Large B-cell lymphomas
 - Diffuse large B-cell lymphoma, NOS
 - Germinal centre B- cell-like subtype (GCB)
 - Activated B-cell-like subtype (ABC)
 - T-cell/histiocyte-rich large B-cell lymphoma
 - Diffuse large B-cell lymphoma/ high grade B-cell lymphoma with MYC and BCL2 rearrangements
 - ALK-positive large B-cell lymphoma
 - Large B-cell lymphoma with IRF4 rearrangement
 - High-grade B-cell lymphoma with 11q aberrations
 - Lymphomatoid granulomatosis
 - EBV-positive diffuse large B-cell lymphoma
 - Diffuse large B-cell lymphoma associated with chronic inflammation
 - Fibrin-associated large B-cell lymphoma
 - Fluid overload-associated large B-cell lymphoma
 - Plasmablastic lymphoma
 - Primary large B-cell lymphoma of immune-privileged sites
 - Primary large B-cell lymphoma of the CNS
 - Primary large B-cell lymphoma of the vitreoretina
 - Primary large B-cell lymphoma of the testis
 - Primary cutaneous diffuse large B-cell lymphoma, leg type
 - Intravascular large B-cell lymphoma
 - Primary mediastinal large B-cell lymphoma
 - Mediastinal grey zone lymphoma
 - High-grade B-cell lymphoma, NOS
- Burkitt lymphoma
 - EBV-positive BL
 - EBV-negative BL
- KSHV/HHV8-associated B-cell lymphoid proliferations and lymphomas
 - KSHV/HHV8-positive diffuse large B-cell lymphoma
 - KSHV/HHV8-positive germinotropic lymphoproliferative disorder

Lymphomas

T-cell and NK-cell Lymphoid Proliferation and Lymphomas

Sub-Classification: Mature T-cell & NK-cell Neoplasms

Mature T-cell and NK-cell leukaemias

- T-large granular lymphocytic leukaemia
- NK-large granular lymphocytic leukaemia
- Adult T-cell leukaemia/lymphoma
- Sezary syndrome
- Aggressive NK-cell leukaemia

Primary cutaneous T-cell lymphomas

- Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder
- Primary cutaneous acral CD8-positive lymphoproliferative disorder
- Mycosis fungoides
- Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: lymphomatoid papulosis
- Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Primary cutaneous gamma/delta T-cell lymphoma
- Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma
- Primary cutaneous peripheral T-cell lymphoma, not otherwise specified

Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas

- Indolent T-cell lymphoma of the gastrointestinal tract
- Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract
- Enteropathy-associated T-cell lymphoma
- Monomorphic epitheliotropic intestinal T-cell lymphoma
- Intestinal T-cell lymphoma not otherwise specified

Hepatosplenic T-cell lymphoma

Anaplastic large cell lymphomas

- ALK-positive anaplastic large cell lymphoma
- ALK-negative anaplastic large cell lymphoma
- Breast implant-associated anaplastic large cell lymphoma

Lymphomas T-Cell Non-Hodgkin Lymphomas (NHL)

Sub-Classification: Mature T-cell & NK-cell Neoplasms

- Nodal T-follicular helper (TFH) lymphomas**
 - Nodal TFH cell lymphoma, angioimmunoblastic-type
 - Nodal TFH cell lymphoma, follicular type
 - Nodal TFH cell lymphoma, not otherwise specified

- Peripheral T-cell lymphoma, not otherwise specified**

- EBV-positive NK/T-cell lymphomas**
 - EBV-positive nodal T- and NK-cell lymphoma
 - Extranodal NK/T-cell lymphoma

- EBV-positive T- and NK-cell lymphoid proliferations and lymphomas of childhood**
 - Severe mosquito bite allergy
 - Hydroa vacciniforme lymphoproliferative disorder
 - Systemic chronic active EBV disease
 - Systemic EBV-positive T-cell lymphoma of childhood

Lymphomas Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD)

Sub-Classification: Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD)

- Lymphoproliferative disease associated with primary immune disorder

- Lymphoma associated with HIV infection

- Post-transplant lymphoproliferative disorder (PTLD)**

- Non-destructive PTLD
 - Plasmacytic hyperplasia PTLD
 - Infectious mononucleosis PTLD
 - Florid follicular hyperplasia PTLD
- Polymorphic PTLD
- Monomorphic PTLD
 - B-cell type
 - T-/NK-cell type
- Classical Hodgkin lymphoma PTLD

- Other immunodeficiency-associated lymphoproliferative disorder



EBMT Centre Identification Code (CIC): _____
 Hospital Unique Patient Number (UPN): _____
 Patient Number in EBMT Registry: _____

Treatment Type HCT CT IST Other
 Treatment Date ____/____/____ (YYYY/MM/DD)

LYMPHOMAS

Hodgkin Lymphomas

DISEASE

Sub-Classification: Hodgkin Lymphomas

<input type="checkbox"/> Nodular lymphocyte predominant
<input type="checkbox"/> Classical predominant; lymphocyte-rich
<input type="checkbox"/> Classical predominant; nodular sclerosis
<input type="checkbox"/> Classical predominant; mixed cellularity
<input type="checkbox"/> Classical predominant; lymphocyte-depleted
<input type="checkbox"/> Classical predominant; NOS
<input type="checkbox"/> Other Hodgkin lymphoma; specify: _____

Haemoglobinopathy

Classification:

- | |
|--|
| <input type="checkbox"/> Thalassaemia |
| <input type="checkbox"/> Sickle Cell Disease |
| <input type="checkbox"/> Other Haemoglobinopathy; specify: _____ |

Solid tumours

Classification:

- | |
|--|
| <input type="checkbox"/> Bone sarcoma (excluding Ewing sarcoma/PNET) |
| <input type="checkbox"/> Breast |
| <input type="checkbox"/> Central nervous system tumours (including CNS/PNET) |
| <input type="checkbox"/> Ewing sarcoma (ES) / PNET, extraskeletal |
| <input type="checkbox"/> Ewing sarcoma (ES) / PNET, skeletal |
| <input type="checkbox"/> Ewing sarcoma (ES)/PNET, not classified |
| <input type="checkbox"/> Germ cell tumour, extragonadal only |
| <input type="checkbox"/> Germ cell tumour, gonadal |
| <input type="checkbox"/> GI tract and Hepatopancreatic cancers |
| <input type="checkbox"/> Kidney cancer excluding Wilm's tumour |
| <input type="checkbox"/> Lung cancer, small cell |
| <input type="checkbox"/> Lung cancer, non small cell (NSCLC) |
| <input type="checkbox"/> Medulloblastoma |
| <input type="checkbox"/> Melanoma |
| <input type="checkbox"/> Nasopharyngeal carcinoma |
| <input type="checkbox"/> Neuroblastoma |
| <input type="checkbox"/> Ovarian (carcinoma) |
| <input type="checkbox"/> Prostate |
| <input type="checkbox"/> Retinoblastoma |
| <input type="checkbox"/> Rhabdomyosarcoma |
| <input type="checkbox"/> Soft tissue sarcoma (excluding Rhabdo and extraskeletal ES) |
| <input type="checkbox"/> Thymoma |
| <input type="checkbox"/> Wilm's tumour |
| <input type="checkbox"/> Other solid tumor; specify: _____ |